Twitter Beğeni Hilesi

In this #JACCCardioOnc review, Dr. David Gent, et al cover the breadth of what is known about #CVD in the adult #HCT population, focusing on acute & late complications, risk prediction, surveillance, & treatment of complications. bit.ly/3ZeW97w #CardioOnc

CONGRESS | #SOHO2024 William Wierda, MD Anderson Cancer Center, presents post hoc exploratory analysis results of the phase I/II TRANSCEND CLL 004 study evaluating characteristics associated with response to liso-cel in pts with R/R CLL/SLL (n=87). OR and CR rates did not correlate with

📢 #RuedaDePrensaSEHH | Se presentan las #cifras del #CáncerSanguíneo en España. 👉El próximo martes 10 de septiembre, #REDECAN y la #SEHH darán a conocer: ✅Proyecciones de la incidencia del cáncer hematológico para 2025 ✅Estimaciones de la #supervivencia ✅Proyecciones y

CONGRESS | #SOHO2024 William Wierda, MD Anderson Cancer Center, discusses whether continuous therapy is the best option for high-risk pts with CLL. In pts with del(17p)/TP53 mutations, second generation covalent BTK inhibitors (such as ibrutinib) show median PFS of 6+ years, however, are

Inspiring talk at European Hematology Association #CRTH2024 by Sirpa Leppa on behalf of the Nordic #Lymphoma Group sharing with scholars 👩🏻‍🎓🧑‍🎓 the best example of collaboration among centers in Nordic countries 🇫🇮🇸🇪🇳🇴🇩🇰 to do research 🔬🩺🧬🧫🧪

Incredibly grateful for being part of this experience. Best group to work with! Yasmina Serroukh Tanya Skrypets Tomáš Kříž Rachael Pocock Raul Cordoba, MD, PhD #WCLLD24 European Hematology Association YoungEHA #CRTH2024

You are all amazing people!! The next generation of #hematologists are ready to 🚀!! #CRTH2024 European Hematology Association YoungEHA #mentoring

Yesterday, EHA #CRTH scholars moved from theory to practice, pairing to present each other's projects in only 2 minutes. Hoping to improve your presentation skills to pitch your clinical trial? The next call for CRTH is now open: eha.fyi/CRTH25

Does your research group collaboration have a mutual need to answer a specific #hematology question? Apply now for #EHA Bilateral Collaborative Grant - offering up to €160,000, this grant helps you build new partnerships in research. Learn more: eha.fyi/BCG2025

Empezamos el curso escolar 📚🤓 recordando la próxima reunión #Cardiotox24 #ILACO 🗓️ 6-8 Noviembre 📍Madrid Actualidad y novedades en clínica e investigación #cardiooncologia 👉🏻 programa: secardiologia.es/images/icagend… No te lo pierdas! SEOM SEOR.es @sehh_es Soc Esp Cardiología

European Hematology Association #CRTH2024 course is coming to end soon. Warm congratulations to all scolars, it has been a great journey, well done, all of you ❤️.

#CRTH2024 has come to its end. Amazing scholars, high expertise faculty, extraordinary organization. Thanks to European Hematology Association for this outstanding #mentoring experience. Proud to be part of it. Looking forward to next year edition. Please, apply!! ehaweb.org/research/resea…

Clinical Research Training in Hematology #CRTH European Hematology Association What a transformative experience!!! Difficult to describe! Finalising 9 months of training with a lot of knowledge, new friends and a sharpened perspective! Highly recommended for those who want to achieve big things!

The call is still open!!! Don’t miss the chance to become one of the 2025 #CRTH scholars, learn from leaders in the field of Hematology & experient statisticians. Connect with young hematologists from all over Europe. Take your medical career to the next level 🚀 European Hematology Association

Thanks to European Hematology Association for this year’s #CRTH2024 Amazing organization, true #mentoring from faculty, amazing places in Europe and outstanding supporting scholars, this is a combination I couldn’t even imagine before.

P E D R O

🚩🚩El envejecimiento NO es lineal. 📈Las proteínas y moléculas del envejecimiento AUMENTAN dramáticamente en dos momentos: —A los 44 años de edad. —A los 60 años de edad.

¡¡Ya han pasado 1️⃣0️⃣ años desde que llegué a Fundación Jiménez Díaz!! Buen momento para hacer balance, ¿no creéis?

CONGRESS |#SOHO2024 | POSTER Santiago Ossorio Prendes at Hospital Universitario Gregorio Marañon, reports 6-year time to next treatment extrapolation curve from the GLOW trial of first-line ibrutinib + venetoclax in elderly/unfit pts with CLL. Projected proportion of patients

CONGRESS | #SOHO2024 | POSTER Arnon P. Kater Amsterdam UMC shared early results of the EPCORE CLL-1 trial of epcortitamab in Richter's transformation (RT). N=38, mFU=12.9 mo, ORR was 53% (60% & 44% in 1L RT & 2L RT, resp), CR rate was 42% (50% & 33% in 1L RT & 2L RT, resp), mOS